Brought to you by 
Elixir gets North American rights to Kissei's diabetes drug
18 Jul 2006
Executive Summary
Japanese pharma Kissei licensed Elixir (genetics-based research of age-related, metabolic diseases) exclusive development and marketing rights to its Type II diabetes drug Glufast (mitiglinide calcium hydrate; formerly KAD1229) in the US, Canada, and Latin America. Elixir also gets rights to any Glufast combination products that are developed.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elixir gets North American rights to Kissei's diabetes drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice